Healthcare

https://techpapersworld.com/wp-content/uploads/2024/11/First-Rounds-of-Late-Breaking-1280x720.jpg

HealthcareFirst Rounds of Late-Breaking Clinical Trial Results Announced at VIVA24

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first two rounds of Late-Breaking Clinical Trials presented at the VIVA24 conference, at Wynn Las Vegas. VIVA (Vascular InterVentional Advances) is an annual vascular education symposium that brings together a global, multispecialty faculty to present a variety of lectures and live case presentations from clinical centers around the world. The...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/Brown-Books-Kids-Publishes-Young-Hockey-Player-1280x720.jpg

HealthcareBrown Books Kids Publishes Young Hockey Player’s Heartfelt Leukemia Survival Story Timed to Hockey Fights Cancer Month

Former Houghton Mifflin Harcourt executive David P. Kavanaugh releases debut children’s book, Dinky Donkey Doo: A Brave Boy, His Loyal Protector, and a Journey of Hope, based on the true story his son Jack — a hockey player, animal lover and leukemia survivor. This captivating story gives young readers a delicate glimpse into a young boy’s cancer journey — bringing about an inspirational message of how kindness and friendship teaches us to stay strong. While undergoing treatment,...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/10/TME-Pharma-Awarded-E2.4-Million-German-1280x720.jpg

HealthcareTME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces that it is awarded a non-refundable grant of €2.4 million from the KMU-innovativ funding program run by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF). The non-dilutive non-refundable funding will support TME Pharma’s planned Phase 2 randomized controlled study evaluating its lead asset, the CXCL12 inhibitor NOX-A12,...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/10/Cancer-trial-retraining-immune-1280x720.jpg

HealthcareCancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough

In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient’s own immune cells to fight cancer. “Cancer often gains the upper hand by suppressing the immune system. Our approach flips the script: we isolate immune cells from this suppressive environment, we reactivate their inherent cancer-fighting abilities in a laboratory, and return them back to the patient”, said Dr Frank Borriello, Founder and CEO of Boston-based Alloplex...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/10/Largest-university-hospital.jpg

HealthcareLargest university hospital in Belgium chooses digital pathology from Sectra to further enhance cancer diagnostics

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed an enterprise imaging contract with Belgium’s largest university hospital, UZ Leuven. The healthcare provider will utilize the module for digital pathology, providing pathologists with a digital solution designed for full-scale primary diagnostics. This will save valuable time for both clinicians and patients, further enhancing cancer care. “We have been using digital pathology in a limited capacity for multiple years. As we now take the step to go...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/05/Study-at-Japans-Kameda-Medical-1-1280x720.jpg

HealthcareOwkin Announces MSIntuit® CRC v2, a Next-Generation AI Diagnostic Aimed at Transforming the Detection and Treatment of Colorectal Cancer

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development, and diagnostics has announced MSIntuit® CRC v21, a next-generation AI solution. Aimed at transforming the detection and treatment of colorectal cancer (CRC), MSIntuit® CRC v2 will initially launch as an RUO version in the US on Roche’s navify® Digital Pathology enterprise software. MSIntuit® CRC v2 builds upon the success of the CE-IVD-certified MSIntuit® CRC, integrating cutting-edge machine learning models developed by Owkin with...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/02/ScreenPoint-Medical-1280x720.jpg

HealthcareOttimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025

Ottimo Pharma, a private biotech company, announces the appointment of world class industry veterans David Epstein as Chair & Chief Executive Officer, Mehdi Shahidi as Head of Development & Chief Medical Officer and James Sabry as Vice-Chair of the Board of Directors. Ottimo Pharma, co-founded by Medicxi and Jonny Finlay in 2020, is developing Jankistomig, a PD1-VEGFR2 bi-functional antibody, designed as a dual-pathway, single agent, IgG therapy targeting immune checkpoint inhibition and angiogenesis in the treatment of cancer. David Epstein, Chair & Chief...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2023/07/Red-e-App-announces-a-new-1280x720.jpg

HealthcareCorvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced impressive three-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the Corvia® Atrial Shunt in selected heart failure patients with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction. The results were published in The American Heart Journal. REDUCE LAP-HF II is the world’s first phase III trial to evaluate safety and efficacy of an atrial...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/07/Neusoft-Remains-No.1-in-China-1280x720.jpg

HealthcarePrime Staffing Defies Industry Trends: Expanding and Hiring Amidst Widespread Healthcare Staffing Layoffs

While the healthcare staffing industry is facing widespread layoffs and downsizing, Prime Staffing, a trusted mainstay in the national healthcare staffing market, is bucking the trend. With an eye toward growth and innovation, Prime Staffing is proud to announce its ongoing expansion, hiring initiatives, and the opening of new offices in India and the Philippines to supplement its U.S.team. In contrast to many firms that are struggling with a slowdown in demand and organizational cutbacks, Prime Staffing is experiencing sustained...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2023/11/Meet-Joey-Rabbit-the-New-1280x720.jpg

HealthcareTASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with edaravone dexborneol (Sanbexin ®) in patients with acute ischemic stroke before endovascular thrombectomy significantly improved the proportion of patients who recovered neurological independence at 90 days and reduced the proportion of patients with disability. Professor Wang Yongjun from Beijing...

Newer Posts

Older Posts